Business Description

Description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Name Current Vs Industry Vs History
Cash-To-Debt 22.68
Equity-to-Asset 0.9
Debt-to-Equity 0.05
Debt-to-EBITDA -0.09
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.12
Distress
Grey
Safe
Beneish M-Score -2.16
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 18.26
Quick Ratio 18.26
Cash Ratio 17.92

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -133.7
Shareholder Yield % -0.83

Financials (Next Earnings Date:2024-05-09 Est.)

LTS:0K1R's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Viridian Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.314
EPS (TTM) ($) -5.32
Beta 0
Volatility % 0
14-Day RSI 0
14-Day ATR ($) 0
20-Day SMA ($) 27.7221
12-1 Month Momentum % 0
52-Week Range ($) 27.7221 - 27.7221
Shares Outstanding (Mil) 62.77

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Viridian Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Viridian Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Viridian Therapeutics Inc Frequently Asked Questions

What is Viridian Therapeutics Inc(LTS:0K1R)'s stock price today?
The current price of LTS:0K1R is $27.72. The 52 week high of LTS:0K1R is $27.72 and 52 week low is $27.72.
When is next earnings date of Viridian Therapeutics Inc(LTS:0K1R)?
The next earnings date of Viridian Therapeutics Inc(LTS:0K1R) is 2024-05-09 Est..
Does Viridian Therapeutics Inc(LTS:0K1R) pay dividends? If so, how much?
Viridian Therapeutics Inc(LTS:0K1R) does not pay dividend.

Press Release

Subject Date
No Press Release